Quanterix Corp (NASDAQ:QTRX) reported fourth-quarter financial results that surpassed analyst revenue expectations, though the market reaction in after-hours trading was muted, with shares edging lower.
The company, a leader in ultra-sensitive biomarker detection, posted revenue of $43.9 million for the quarter ended December 31, 2025, representing a 25% increase from the $35.2 million reported in the same period last year. This figure notably exceeded the consensus analyst estimate of $38.9 million. On the bottom line, the company reported a non-GAAP adjusted loss per share of $0.38, which was narrower than the anticipated loss of $0.46 per share.
Financial Performance vs. Estimates
The core financial results for the quarter presented a mixed but generally positive picture relative to Wall Street forecasts.
- Revenue: Reported $43.9M vs. Estimate of $38.9M (Beat by ~12.8%)
- Non-GAAP EPS: Reported -$0.38 vs. Estimate of -$0.46 (Beat by ~$0.08)
- Full-Year 2025 Revenue: $138.9 million, a modest 1% increase from $137.4 million in 2024.
The quarterly beat was driven by strong product revenue, which grew to $29.2 million from $20.5 million in the prior year. However, profitability metrics showed pressure, with GAAP gross margin declining to 45.7% from 63.0% a year ago, which the company attributed to product mix and costs associated with its recent acquisition of Akoya Biosciences. Adjusted EBITDA was a loss of $7.9 million, compared to a loss of $5.9 million in Q4 2024.
Market Reaction and Strategic Context
Following the earnings release, shares of Quanterix traded slightly lower in the after-market session. This muted reaction, despite the top and bottom-line beats, may reflect investor focus on the company's ongoing losses, margin compression, and the significant cash used in operations for the full year ($77.2 million). The market is likely weighing the strong quarterly sales performance against the longer-term path to sustained profitability.
The earnings report was accompanied by significant strategic updates from new President & CEO Everett Cunningham, who joined the company during the quarter. He emphasized that the company is now shifting its focus from integration to driving growth, with a goal of achieving cash flow breakeven in the second half of 2026.
Key Business Highlights and Forward Guidance
Beyond the financials, Quanterix announced several operational milestones that are critical to its future, particularly in the high-potential Alzheimer's disease diagnostics market.
- Alzheimer's Diagnostic Milestone: The company submitted a 510(k) premarket notification to the FDA in January 2026 for its multi-analyte blood test for Alzheimer's disease.
- Reimbursement Progress: The Centers for Medicare & Medicaid Services (CMS) established a national reimbursement rate of $897 for its LucentAD Complete test, a crucial step for commercial adoption.
- Integration Synergies: The company stated it has realized $74 million of the planned cost savings from its Akoya Biosciences acquisition, with 94% of integration milestones complete.
For the full year 2026, Quanterix provided its initial guidance, projecting revenue in the range of $169 million to $174 million. This outlook is closely aligned with the current analyst sales estimate of $174.3 million for the year. The company also expects to exit 2026 with approximately $100 million in cash and no debt.
Conclusion
Quanterix delivered a solid quarter of revenue growth that outpaced expectations, demonstrating commercial traction even amidst a year of significant acquisition-related integration. The narrowed adjusted EPS loss also indicates some progress on cost management. The company's future hinges on successfully commercializing its Alzheimer's diagnostic blood test and realizing the full potential of its expanded platform. While the financial losses and cash burn remain areas for investor scrutiny, the established reimbursement pathway and clear 2026 targets for cash flow breakeven provide a tangible framework for evaluating progress.
For a detailed breakdown of future quarterly estimates and historical earnings performance, you can review the Quanterix earnings and estimates page here.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, nor a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
